Description: Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.
Home Page: www.imugene.com
4-6 Bligh Street
Sydney,
NSW
2000
Australia
Phone:
61 3 9824 5254
Officers
| Name | Title |
|---|---|
| Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD | Exec. Chairman |
| Ms. Leslie Chong | CEO, MD & Exec. Director |
| Dr. Nicholas J. Ede B.Sc.(Hons.), Ph.D. | Chief Technology Officer |
| Dr. Monil Shah M.B.A., Pharm.D. | Chief Bus. Officer |
| Mr. Michael Tonroe ACA, B.Sc., Bsc(Hons), F.C.A., M.A.I.C.D., MAICD | Chief Financial Officer |
| Ms. Ursula McCurry | Sr. VP of Clinical Operations |
| Dr. Giovanni Selvaggi | Chief Medical Officer |
| Mr. Nathan Jong C.A. | Joint Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.5063 |
| Price-to-Sales TTM: | 61.8412 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 0 |